These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14607764)

  • 41. Treatment of heparin-induced thrombocytopenia with fondaparinux.
    Harenberg J; Jörg I; Fenyvesi T
    Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?
    Lubenow N; Hinz P; Ekkernkamp A; Greinacher A
    Eur J Haematol; 2007 Sep; 79(3):187-90. PubMed ID: 17655709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unfractionated heparin and other antithrombin mediated anticoagulants.
    Adler BK
    Clin Lab Sci; 2004; 17(2):113-7. PubMed ID: 15168893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
    Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.
    Nutescu EA; Wittkowsky AK; Dobesh PP; Hawkins DW; Dager WE
    Ann Pharmacother; 2006 Sep; 40(9):1558-71. PubMed ID: 16912250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention and management of venous thromboembolism in pregnancy.
    James AH
    Am J Med; 2007 Oct; 120(10 Suppl 2):S26-34. PubMed ID: 17916457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A study of 19 cases of allergy to heparins with positive skin testing].
    Phan C; Vial-Dupuy A; Autegarden JE; Amsler E; Gaouar H; Abuaf N; Pecquet C; Francès C; Soria A
    Ann Dermatol Venereol; 2014 Jan; 141(1):23-9. PubMed ID: 24461090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cutaneous delayed hypersensitivity reactions to heparins and heparinoids].
    Figarella I; Barbaud A; Lecompte T; De Maistre E; Reichert-Penetrat S; Schmutz JL
    Ann Dermatol Venereol; 2001 Jan; 128(1):25-30. PubMed ID: 11226896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tolerance of Fondaparinux in Immediate-type Hypersensitivity to Heparins.
    Trog LM; Kahle B; Schindewolf M; Jappe U; Ludwig RJ
    Am J Med; 2015 Nov; 128(11):e21-2. PubMed ID: 26169891
    [No Abstract]   [Full Text] [Related]  

  • 54. Heparin-induced thrombocytopenia successfully treated with fondaparinux.
    Seldrum S; Lambert M; Hainaut P
    Acta Clin Belg; 2009; 64(2):144-6. PubMed ID: 19432027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.
    Dager WE; Andersen J; Nutescu E
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):88S-94S. PubMed ID: 15317404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heparin-induced skin necrosis and low molecular weight heparins.
    Drew PJ; Smith MJ; Milling MA
    Ann R Coll Surg Engl; 1999 Jul; 81(4):266-9. PubMed ID: 10615196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
    Walenga JM; Fareed J; Jeske WP; Bıck RL; Samama MM
    Turk J Haematol; 2002 Jun; 19(2):137-50. PubMed ID: 27264755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fondaparinux (Arixtra), a new anticoagulant.
    Med Lett Drugs Ther; 2002 May; 44(1130):43-4. PubMed ID: 12011755
    [No Abstract]   [Full Text] [Related]  

  • 59. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
    Bauer KA
    Chest; 2003 Dec; 124(6 Suppl):364S-370S. PubMed ID: 14668419
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fondaparinux Sodium: Recent Advances in the Management of Thrombosis.
    Bauersachs RM
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484221145010. PubMed ID: 36594404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.